New fund brings a new strategy to healthcare and life sciences
Dimension is a first-of-its-kind firm partnering with founders at the interface of technology and life sciences to transform the trajectory of life on earth.
Welcome a new and large player to the biotech/life sciences sector with a unique strategy.
Co-founded by three venture capital partners, including two with former ties to Lux Capital, the new firm named Dimension describes itself as “a first-of-its-kind firm partnering with founders at the interface of technology and life sciences to transform the trajectory of life on earth.”
It is backed by an oversubscribed $350 initial raise and is focused on investing at the earliest stages – incubation through growth – of drug discovery platforms, machine learning, tools, services, instruments, and software companies digitizing the world of life sciences
“The digitization of life sciences will transform the entire end-to-end journey of medicines: from the Eureka moment of biological discovery, to lab tools, instruments and software, to clinical development, to regulatory interface, and ultimately to manufacturing and commercialization,” the company wrote on its LinkedIn webpage. “And tomorrow’s biotechs will no longer be formed by a team of two: a biologist and a chemist, but instead a team of three: a biologist, chemist, and computer scientist.
We founded Dimension to partner with the very best entrepreneurs working across this continuum while aspiring to become a beacon and lighthouse for the greater and emerging ecosystem.”
